Update on asthma–copd overlap (Aco): A narrative review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- COPD-312560-update-on-asthma---copd-overlap--aco---a-narrative-review
Forlagets udgivne version, 1,9 MB, PDF-dokument
Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was introduced to describe patients that have clinical features of both diseases and may represent around 25% of COPD patients and around 20% of asthma patients. Despite the increasing interest in ACO, there are still substantial controversies regarding its definition and its position within clinical guidelines for patients with obstructive lung disease. In general, most definitions indicate that ACO patients must present with non-reversible airflow limitation, significant exposure to smoking or other noxious particles or gases, together with features of asthma. In patients with a primary diagnosis of COPD, the identification of ACO has therapeutic implication because the asthmatic component should be treated with inhaled corticosteroids and some studies suggest that the most severe patients may respond to biological agents indicated for severe asthma. This manuscript aims to summarize the current state-of-the-art of ACO. The definitions, prevalence, and clinical manifestations will be reviewed and some innovative aspects, such as genetics, epigenetics, and biomarkers will be addressed. Lastly, the management and prognosis will be outlined as well as the position of ACO in the COPD and asthma guidelines.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | International Journal of Chronic Obstructive Pulmonary Disease |
| Vol/bind | 16 |
| Sider (fra-til) | 1783-1799 |
| Antal sider | 17 |
| ISSN | 1178-2005 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
Evgeni Mekov has received grants and personal fees from Chiesi, and speaker or consulting fees from Astra Zeneca and Chiesi. Alexa Nuñez is the recipient of a Rio Hortega contract in the 2019 Strategic Action Health Call from the Instituto de Salud Carlos III for the years 2020–2022. Don D. Sin has received honoraria for speaking engagements on COPD topics from AstraZeneca, Boehringer Ingelheim and has sat on advisory boards of AZ, Grifols and Nuvaira. Masakazu Ichinose has received honoraria for speaking from AstraZeneca, Nippon Boehringer Ingelheim, Kyorin and Novartis Pharma. Chin Kook Rhee reports personal fees from MSD and consulting/lecture fees from AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, Sanofi, and Bayer, outside the submitted work. Diego Jose Maselli reports personal fees from GlaxoSmithKline, AstraZeneca and Sanofi Regeneron GSK, Genentech, and Sunovion, during the conduct of the study. Andréanne Coté reports grants from GlaxoSmithKline personal fees from Sanofi Regeneron, and consulting and speaker fees on asthma topics from AstraZeneca, GlaxoSmithKline and Sanofi. Charlotte Suppli Ulrik has received speaker fees and/or research grants from AstraZeneca, GSK, Boehringer-Ingelheim, Chiesi, TEVA, Mundipharma, Sandoz, Actelion, Orion Pharma, Novartis, Sanofi Genzyme and ALK-Abello and has been on advisory boards for AstraZeneca, GSK, Boehringer-Ingelheim, Chiesi, Novartis, Sanofi Genzyme and TEVA. Francois Maltais reports grants from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, GSK, Sanofi, Grifols, and Novartis, and personal fees for serving on speaker bureaus and consultation panels from GlaxoSmithKline, Boehringer Ingelheim, Grifols, and Novartis; he is financially involved with Oxynov, a company which is developing an oxygen delivery system. Antonio Anzueto has received consultant fees from AstraZeneca, Boehringer Ingelheim, Grifols; GlaxoSmithKline, Verona Pharma, TEVA, Mylan/ Theravance. Marc Miravitlles has received speaker/personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols and research grants from Grifols. The authors reported no other potential conflicts of interest for this work.
Publisher Copyright:
© 2021 Mekov et al.
ID: 274619573